Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2001 1
2002 1
2003 2
2004 2
2005 1
2006 3
2007 1
2008 3
2009 6
2010 2
2011 5
2012 9
2013 6
2014 4
2015 9
2016 3
2017 2
2019 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: hoeflich kp. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
p21-activated kinase inhibitors.
Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. Rudolph J, et al. Among authors: hoeflich kp. Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Enzymes. 2013. PMID: 25034104 Review.
Targeting cancer with kinase inhibitors.
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Gross S, et al. Among authors: hoeflich kp. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. J Clin Invest. 2015. PMID: 25932675 Free PMC article. Review.
p21-activated kinase 1: PAK'ed with potential.
Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: hoeflich kp. Oncotarget. 2011 Jun;2(6):491-6. doi: 10.18632/oncotarget.271. Oncotarget. 2011. PMID: 21653999 Free PMC article. Review.
p21-Activated kinase inhibitors: a patent review.
Crawford JJ, Hoeflich KP, Rudolph J. Crawford JJ, et al. Among authors: hoeflich kp. Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Expert Opin Ther Pat. 2012. PMID: 22404134 Review.
Radixin: cytoskeletal adopter and signaling protein.
Hoeflich KP, Ikura M. Hoeflich KP, et al. Int J Biochem Cell Biol. 2004 Nov;36(11):2131-6. doi: 10.1016/j.biocel.2003.11.018. Int J Biochem Cell Biol. 2004. PMID: 15313460 Review.
Inhibitors of p21-activated kinases (PAKs).
Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Rudolph J, et al. Among authors: hoeflich kp. J Med Chem. 2015 Jan 8;58(1):111-29. doi: 10.1021/jm501613q. Epub 2014 Dec 3. J Med Chem. 2015. PMID: 25415869
Regulation of ERK3/MAPK6 expression by BRAF.
Hoeflich KP, Eby MT, Forrest WF, Gray DC, Tien JY, Stern HM, Murray LJ, Davis DP, Modrusan Z, Seshagiri S. Hoeflich KP, et al. Int J Oncol. 2006 Oct;29(4):839-49. Int J Oncol. 2006. PMID: 16964379
62 results